Outcomes based on prior VEGFR TKI and PD-1 checkpoint inhibitor therapy in METEOR, a randomized phase 3 trial of cabozantinib (C) vs everolimus (E) in advanced renal cell carcinoma (RCC) Meeting Abstract
| Authors: | Powles, T.; Motzer, R. J.; Escudier, B. J.; Pal, S. K.; Kollmannsberger, C. K.; Pikiel, J.; Gurney, H.; Rha, S. Y.; Park, S. H.; Geertsen, P. F.; Gross-Goupil, M.; Grande, E.; Suarez, C.; Arroyo, A. M.; Dean, M.; George, D.; Choueiri, T. K. |
| Abstract Title: | Outcomes based on prior VEGFR TKI and PD-1 checkpoint inhibitor therapy in METEOR, a randomized phase 3 trial of cabozantinib (C) vs everolimus (E) in advanced renal cell carcinoma (RCC) |
| Meeting Title: | 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 34 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2016 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2016-05-20 |
| Start Page: | 258s |
| Language: | English |
| ACCESSION: | WOS:000404665407130 |
| DOI: | 10.1200/JCO.2016.34.15_suppl.4557 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 4557 -- Source: Wos |
